Founded in 2005, by Alexandre TOKAY, CEO, and Dr. Michel KHRESTCHATISKY, Scientific Advisor, VECT-HORUS is a spin-off of the NICN UMR7259 (CNRS and Aix-Marseille University) now Institute for NeuroPhysiopathology (INP) directed by Dr. Michel KHRESTCHATISKY (UMR7051, CNRS AMU). Based in Marseille, France, the company has 38 employees, mostly in R&D. To strengthen its leadership, the company has brought together a team of exceptional leaders from the Pharma/Biotech industry.
Founders & management
Scientific advisory board
Six renowned scientists and experts in neuropharmacology, oncology and molecular engineering bring their expertise to VECT-HORUS.
Financial & Academic Partners
Financial partners
VECT-HORUS continues its funding strategy with historic shareholders and also new entrants to grant the Company significant financial resources to carry out its research and development programs and leverage with public research grants.
Vect-Horus received the agreement of Région Sud - Provence-Alpes-Côte d’Azur for a non-dilutive grant of more than 1 M€ from the REACT-EU program. This project is financed with the assistance of the European Union with the European Regional Development Fund in response to the COVID-19 pandemic.
Vect-Horus plans to optimize its R&D and production equipment to accelerate the demonstration of its technology VECTrans® and to ensure its development on a larger scale to meet the needs of its Pharma/Biotech partners and new challenges in therapy, in particular, in the development of innovative therapeutic approaches based on nucleic acids (siRNAs, ASOs, mRNAs) which require targeting and cellular transport technologies.
Academic partners
Close collaborations with top academic research centers: AMU, CEA, CERIMED, CNRS, INP, INSERM